Baxter International Inc. (NYSE:BAX), a global innovator in renal care for more than 60 years, today announced its recently launched SHARESOURCE remote patient management system has helped healthcare providers manage more than 150,000 peritoneal dialysis (PD) treatments performed in patients’ homes. The treatment milestone represents the large-scale application of the first and only two-way, telehealth platform to support home dialysis therapy.
“From urban to rural locations around the world, healthcare providers are quickly adopting Baxter’s SHARESOURCE technology with either AMIA or HOMECHOICE CLARIA automated peritoneal dialysis systems,” says Giuseppe Accogli, corporate vice president and president, Baxter Renal. “Baxter’s new APD systems with SHARESOURCE are designed to help more patients gain access to home dialysis therapy and provide their physicians with greater ability to remotely manage their care.”
Baxter’s SHARESOURCE remote patient management system is a two-way, cloud-based technology platform that allows designated healthcare providers to securely view recently completed dialysis-related treatment data that is automatically collected after each PD session. Healthcare providers can act on this information by securely and remotely adjusting their patients’ home device settings without requiring patients to travel to the clinic. The SHARESOURCE system also provides a patient’s healthcare team better visibility to their missed treatments. The healthcare provider can then proactively follow up with their patient to address any potential issues.
The recently launched telehealth platform is offered with Baxter’s AMIA and HOMECHOICE CLARIA automated peritoneal dialysis (APD) systems, where those systems are cleared for use worldwide.
In the United States, SHARESOURCE is available on Baxter’s AMIA APD system. The AMIA system has advanced features such as animated graphics and automated step-by-step instructions with voice guidance. The system was designed to provide a user-friendly experience that helps guide patients through their home therapy. AMIA also is up to 40 percent smaller and 30 percent lighter than other cyclers on the market, and features a folding design when the touch screen is not in use.1, 2 The compact design means AMIA can be packed in a car or taken onboard an airplane, enabling patients to conduct therapy when traveling for work or leisure.
HOMECHOICE CLARIA with SHARESOURCE is available in select European and Asian countries and has recently launched in Latin America. The system features a large, two-line display screen for better visibility, and a universal interface that is available in 41 languages.
PD works by cleaning the blood of toxins and removing extra fluid through the body’s peritoneal cavity. The ability to choose when and where therapy is done means APD may offer lifestyle benefits, such as being able to work during normal business hours. One study concluded patients who maintained the same level of employment during the six months prior to kidney failure, were significantly more likely to choose PD as their initial therapy.3
For prescription only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.
About Baxter International Inc.
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning Baxter's AMIA and HOMECHOICE CLARIA APD systems and the SHARESOURCE connectivity platform, including anticipated benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; changes in law and regulations; breaches or failures of the company’s information technology systems; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Baxter, Amia, HomeChoice Claria and Sharesource are registered trademarks of Baxter International Inc.
1 Amia Automated PD System Patient Guide. Baxter Healthcare
Corporation. Deerfield, IL.
2 HomeChoice and HomeChoice PRO APD Systems Patient At-Home Guide. Baxter Healthcare Corporation. Deerfield, IL.
3 Muehrer, Rebecca J., et al. Factors Affecting Employment at Initiation of Dialysis. CJASN. March 2011. vol. 6 no. 3 489-496
View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005310/en/Business Wire
Last updated on: 19/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.